No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1144-1152
Number of pages9
JournalNeurology
Volume88
Issue number12
DOIs
Publication statusPublished - 2017

Keywords

  • immunosuppressive agent
  • natalizumab
  • immunologic factor
  • natalizumab, adult
  • Article
  • cerebrospinal fluid analysis
  • clinical outcome
  • drug induced disease
  • drug withdrawal
  • Expanded Disability Status Scale
  • female
  • groups by age
  • human
  • immunosuppressive treatment
  • JC virus
  • major clinical study
  • male
  • meta analysis
  • mortality risk
  • multiple sclerosis
  • outcome assessment
  • overall survival
  • plasmapheresis
  • priority journal
  • progressive multifocal leukoencephalopathy
  • retrospective study
  • sex difference
  • systematic review
  • disability
  • Leukoencephalopathy, Progressive Multifocal
  • Medline
  • middle aged
  • mortality
  • nonparametric test
  • procedures
  • statistics and numerical data
  • treatment outcome, Adult
  • Disability Evaluation
  • Female
  • Humans
  • Immunologic Factors
  • Male
  • Middle Aged
  • Multiple Sclerosis
  • Natalizumab
  • Plasmapheresis
  • PubMed
  • Retrospective Studies
  • Statistics, Nonparametric
  • Treatment Outcome

Cite this